The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The role of neoadjuvant chemotherapy in elderly patients with borderline or locally advanced pancreatic cancer: Is it safe and feasible?
 
Atsushi Oba
No Relationships to Disclose
 
Christopher Hanyoung Lieu
Consulting or Advisory Role - Foundation Medicine; Foundation Medicine; Foundation Medicine; Foundation Medicine; Ipsen; Ipsen; Ipsen; Ipsen
Research Funding - Merck; Merck; Merck; Merck
Other Relationship - Immune Design; Immune Design; Immune Design; Immune Design
 
Cheryl Lauren Meguid
No Relationships to Disclose
 
Sarah Lindsey Davis
No Relationships to Disclose
 
Alexis Diane Leal
Research Funding - Aduro Biotech (Inst); Aduro Biotech (Inst); Aduro Biotech (Inst); Aduro Biotech (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Aduro Biotech; Aduro Biotech; Aduro Biotech; Aduro Biotech; Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; Ipsen; Ipsen; Ipsen; Ipsen
 
Tom Purcell
No Relationships to Disclose
 
Gentry Teng King
No Relationships to Disclose
 
Karyn A. Goodman
Consulting or Advisory Role - RenovoRx; RenovoRx; RenovoRx; RenovoRx
Research Funding - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca
 
Tracey E. Schefter
No Relationships to Disclose
 
Ana Luiza Gleisner
No Relationships to Disclose
 
Steven Arthur Ahrendt
No Relationships to Disclose
 
Stephen Leong
Stock and Other Ownership Interests - Antares Pharmaceuticals; Antares Pharmaceuticals; Antares Pharmaceuticals; Antares Pharmaceuticals; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals
Honoraria - Lilly; Lilly; Lilly; Lilly
Research Funding - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); Deciphera (Inst); Deciphera (Inst); Deciphera (Inst); Karyopharm Therapeutics (Inst); Karyopharm Therapeutics (Inst); Karyopharm Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche
 
Wells A. Messersmith
Consulting or Advisory Role - Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Purdue Pharma (Inst); Purdue Pharma (Inst); Purdue Pharma (Inst); Purdue Pharma (Inst); Tanabe Research (Inst); Tanabe Research (Inst); Tanabe Research (Inst); Tanabe Research (Inst)
Research Funding - Aduro Biotech (Inst); Aduro Biotech (Inst); Aduro Biotech (Inst); Aduro Biotech (Inst); Alexo Therapeutics (Inst); Alexo Therapeutics (Inst); Alexo Therapeutics (Inst); Alexo Therapeutics (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Beigene (Inst); Beigene (Inst); Beigene (Inst); Beigene (Inst); D3 (Inst); D3 (Inst); D3 (Inst); D3 (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); Immunomedics (Inst); OncoMed (Inst); OncoMed (Inst); OncoMed (Inst); OncoMed (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Richard D. Shulick
No Relationships to Disclose
 
Marco Del Chiaro
No Relationships to Disclose